NeuroVive Pharmaceutical AB Anno IPO
Cos'è Anno IPO di NeuroVive Pharmaceutical AB?
Anno IPO di NeuroVive Pharmaceutical AB è 2018
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su OTC rispetto a NeuroVive Pharmaceutical AB
Cosa fa NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Aziende con anno ipo simili a NeuroVive Pharmaceutical AB
- Mediawan SA ha Anno IPO di 2017
- Southern ha Anno IPO di 2017
- Polytec Hldg Ag Inh. Eo 1 ha Anno IPO di 2017
- Roots Sustainable Agricultural Technologies ha Anno IPO di 2017
- Galena Mining ha Anno IPO di 2017
- MVC Capital Inc ha Anno IPO di 2017
- NeuroVive Pharmaceutical AB ha Anno IPO di 2018
- Bermele plc ha Anno IPO di 2019
- Twin River Worldwide ha Anno IPO di 2019
- Contel Technology ha Anno IPO di 2019
- GraniteShares 3x Long Diageo Daily ETC ha Anno IPO di 2019
- Pinterest Inc ha Anno IPO di 2019
- Ferrellgas Partners, L.P ha Anno IPO di 2019